Pancreatic Cancer Research

ResearcherAndalusian Health ServiceNo recent work listed

Manuel Benavides

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9817-1291; OpenAlex author ID A5054498659. Sources: ClinicalTrials.gov.

Their work

Papers
6 (first author 1, last author 0)
Trials
1
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2011: 1 trial · 2012: none · 2013: none · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper

Papers 6

  1. Phase I/II trial of sequential treatment of nab-paclitaxel in combination with gemcitabine followed by modified FOLFOX chemotherapy in patients with untreated … Co-author DOI 10.1016/j.ejca.2020.07.035↗
  2. Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: Results of the PANOVA phase 2 study. First author DOI 10.1016/j.pan.2018.10.004↗
  3. Integrative multi-platform meta-analysis of gene expression profiles in pancreatic ductal adenocarcinoma patients for identifying novel diagnostic biomarkers. Co-author DOI 10.1371/journal.pone.0194844↗
  4. Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety … Co-author DOI 10.1016/j.ejca.2016.12.032↗
  5. Identification of gene expression profiling associated with erlotinib-related skin toxicity in pancreatic adenocarcinoma patients. Co-author DOI 10.1016/j.taap.2016.10.003↗
  6. TTD consensus document on the diagnosis and management of exocrine pancreatic cancer. Co-author DOI 10.1007/s12094-014-1177-7↗

Trials 1

  1. Safety and Efficacy Study of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic Cancer Study chair NCT01303029↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Carmen Guillén‐Ponce · 5 shared papers, 2016–2020 · strength 0.40
  2. Javier Gallego-Plazas · 5 shared papers, 2014–2019 · strength 0.33
  3. Enrique Aranda Aguilar · 5 shared papers, 2014–2020 · strength 0.32
  4. Fernando Rivera Herrero · 3 shared papers, 2014–2019 · strength 0.20
  5. Antonio Irigoyen · 3 shared papers, 2016–2018 · strength 0.18
  6. Alfredo Carrato Mena · 2 shared papers, 2014–2020 · strength 0.14
  7. Carolina Torres · 2 shared papers, 2016–2018 · strength 0.13
  8. Jose Carlos Prados · 2 shared papers, 2016–2018 · strength 0.13
  9. Octavio Caba · 2 shared papers, 2016–2018 · strength 0.13
  10. Cristina Jiménez‐Luna · 2 shared papers, 2016–2018 · strength 0.13
  11. Marc Küng · 1 shared paper, 2019 · strength 0.11
  12. Susana Rodríguez Martínez · 1 shared paper, 2020 · strength 0.10
  13. Antonio Irigoyen · 1 shared trial, 2011 · strength 0.08
  14. Joaquina Martínez-Galán · 1 shared paper, 2017 · strength 0.05
  15. José Luis Manzano Mozo · 1 shared paper, 2017 · strength 0.05
  16. Ruth Vera · 1 shared paper, 2017 · strength 0.05
  17. Marta Martín-Richard · 1 shared paper, 2017 · strength 0.05
  18. Roberto Pazo-Cid · 1 shared paper, 2017 · strength 0.05
  19. Josep M. Tabernero · 1 shared paper, 2014 · strength 0.04
  20. Carles Pericay Pijaume · 1 shared paper, 2014 · strength 0.04
  21. Berta Laquente · 1 shared paper, 2014 · strength 0.04
  22. Jesús García‐Foncillas López · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.